Arcellx, Inc.ACLXEarnings & Financial Report
Arcellx, Inc. is a clinical-stage biotechnology company that develops innovative chimeric antigen receptor T (CAR-T) cell therapies for treating hard-to-treat cancers including hematologic malignancies and solid tumors. Its core pipeline targets unmet oncology medical needs, serving global patient populations and partnering with life sciences stakeholders.
ACLX Q1 FY2025 Key Financial Metrics
Revenue
$8.1M
Gross Profit
N/A
Operating Profit
$-68.9M
Net Profit
$-62.3M
Gross Margin
N/A
Operating Margin
-847.6%
Net Margin
-766.0%
YoY Growth
-79.3%
EPS
$-1.13
Arcellx, Inc. Q1 FY2025 Financial Summary
Arcellx, Inc. reported revenue of $8.1M (down 79.3% YoY) for Q1 FY2025, with a net profit of $-62.3M (down 765.1% YoY) (-766.0% margin).
Key Financial Metrics
| Total Revenue | $8.1M |
|---|---|
| Net Profit | $-62.3M |
| Gross Margin | N/A |
| Operating Margin | -847.6% |
| Report Period | Q1 FY2025 |
Arcellx, Inc. Annual Revenue by Year
Arcellx, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $107.9M).
Arcellx, Inc. Quarterly Revenue & Net Profit History
Arcellx, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2025 | $8.1M | -79.3% | $-62.3M | -766.0% |
| Q4 FY2024 | $15.3M | -75.8% | $-47.1M | -308.4% |
| Q3 FY2024 | $26.0M | +74.0% | $-25.9M | -99.4% |
| Q2 FY2024 | $27.4M | +91.5% | $-27.2M | -99.3% |
| Q1 FY2024 | $39.3M | +119.2% | $-7.2M | -18.3% |
| Q4 FY2023 | $63.1M | — | $19.8M | 31.4% |
| Q3 FY2023 | $15.0M | — | $-39.3M | -263.0% |
| Q2 FY2023 | $14.3M | — | $-23.9M | -166.8% |
Income Statement
| Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.3M | $15.0M | $63.1M | $39.3M | $27.4M | $26.0M | $15.3M | $8.1M |
| YoY Growth | N/A | N/A | N/A | 119.2% | 91.5% | 74.0% | -75.8% | -79.3% |
Balance Sheet
| Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $623.5M | $614.2M | $825.1M | $779.7M | $734.3M | $764.9M | $711.3M | $648.1M |
| Liabilities | $329.9M | $348.1M | $339.8M | $283.1M | $247.1M | $281.9M | $256.5M | $231.2M |
| Equity | $293.7M | $266.1M | $485.4M | $496.6M | $487.2M | $483.0M | $454.8M | $416.9M |
Cash Flow
| Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-22.6M | $-10.1M | $58.2M | $-31.9M | $-36.2M | $30.7M | $-46.0M | $-63.1M |